Dr. Lal PathLabs
BSE 539524 · ISIN INE600L01024
9 stories, newest first.
- Dr Lal PathLabs completed acquisition of the remaining 30% stake in Suburban Diagnostics (Straterpath Labs) at over Rs 1,600 per share
- Dr. Lal PathLabs: PathLabs Unifiers buys remaining 30% of Centrapath Labs at INR 1608.352 per share, CPL now wholly owned
- Dr. Lal PathLabs invests up to INR 30.3 crore in WOS PathLabs Unifiers to fund buyout of remaining 30% of CentraPath Labs
- Income Tax Dept appeals before ITAT against relief on ESOP expense disallowance
- Update on completion of acquisition of stake in SN Genelab Private Limited
- Kush Bohra reiterated a buy call on Dr. Lal Path Labs after it held ground for most of the day before slipping late
- Completes Acquisition of 80% Stake in Sunshine Healthcare, Ghana
- Board Meeting on November 4, 2026 for Q2 and Half-Year Results; Trading Window Closed
- Board approves acquisition of 70% stake in SN Genelab Private Limited
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.